Correlation Between Elevation Oncology and Recursion Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Elevation Oncology and Recursion Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Elevation Oncology and Recursion Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Elevation Oncology and Recursion Pharmaceuticals, you can compare the effects of market volatilities on Elevation Oncology and Recursion Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Elevation Oncology with a short position of Recursion Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Elevation Oncology and Recursion Pharmaceuticals.

Diversification Opportunities for Elevation Oncology and Recursion Pharmaceuticals

0.49

Correlation Coefficient

Elevation Oncology  Recursion Pharmaceuticals

Very weak diversification

The 3 months correlation between Elevation and Recursion is 0.49. Overlapping area represents the amount of risk that can be diversified away by holding Elevation Oncology and Recursion Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Recursion Pharmaceuticals and Elevation Oncology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Elevation Oncology are associated (or correlated) with Recursion Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Recursion Pharmaceuticals has no effect on the direction of Elevation Oncology i.e., Elevation Oncology and Recursion Pharmaceuticals go up and down completely randomly.

Pair Corralation between Elevation Oncology and Recursion Pharmaceuticals

Given the investment horizon of 90 days Elevation Oncology is expected to generate 1.54 times less return on investment than Recursion Pharmaceuticals. But when comparing it to its historical volatility, Elevation Oncology is 1.1 times less risky than Recursion Pharmaceuticals. It trades about 0.02 of its potential returns per unit of risk. Recursion Pharmaceuticals is currently generating about 0.02 of returns per unit of risk over similar time horizon. If you would invest  550.00  in Recursion Pharmaceuticals on April 17, 2025 and sell it today you would lose (11.00) from holding Recursion Pharmaceuticals or give up 2.0% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Elevation Oncology  vs.  Recursion Pharmaceuticals

Elevation Oncology

Risk-Adjusted Performance

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Elevation Oncology are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of fairly stable technical and fundamental indicators, Elevation Oncology is not utilizing all of its potentials. The latest stock price fuss, may contribute to near-short-term losses for the sophisticated investors.

Recursion Pharmaceuticals

Risk-Adjusted Performance

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Recursion Pharmaceuticals are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Recursion Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in August 2025.

Pair Trading with Elevation Oncology and Recursion Pharmaceuticals

The main advantage of trading using opposite Elevation Oncology and Recursion Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Elevation Oncology position performs unexpectedly, Recursion Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Recursion Pharmaceuticals will offset losses from the drop in Recursion Pharmaceuticals' long position.

The idea behind Elevation Oncology and Recursion Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.